Lee et al. used CRISPR/Cas9 libraries to screen human lung cancer cell lines (NCI-H820) and knockdown of the genes MDM4, PSMA6, PSMB6, ANAPC5, and CDK1 increased the sensitivity of lung cancer cells to the EGFR-TKI Erlotinib, the MDM4 inhibitor nutlin-3 synergized with PSMA6, and the PSMB6 inhibitor Carfilzomib synergized with Erlotinib in vitro cell lines and in vivo patient-derived xenograft experiments, can promote tumor cell death, target cell cycle or protein ubiquitination pathways, and may inhibit Erlotinib resistance progression (Lee et al., 2021). The gene discussed is ANAPC5; the disease is lung carcinoma.